560 related articles for article (PubMed ID: 27855494)
21. Carboplatin loaded Surface modified PLGA nanoparticles: Optimization, characterization, and in vivo brain targeting studies.
Jose S; Juna BC; Cinu TA; Jyoti H; Aleykutty NA
Colloids Surf B Biointerfaces; 2016 Jun; 142():307-314. PubMed ID: 26970818
[TBL] [Abstract][Full Text] [Related]
22. Loteprednol Etabonate Nanoparticles: Optimization via Box-Behnken Design Response Surface Methodology and Physicochemical Characterization.
Sah AK; Suresh PK
Curr Drug Deliv; 2017; 14(5):676-689. PubMed ID: 27480117
[TBL] [Abstract][Full Text] [Related]
23. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
24. PLGA nanoparticles for intravitreal peptide delivery: statistical optimization, characterization and toxicity evaluation.
Bisht R; Rupenthal ID
Pharm Dev Technol; 2018 Apr; 23(4):324-333. PubMed ID: 27670289
[TBL] [Abstract][Full Text] [Related]
25. Preparation and characterization of polymeric nanoparticles surface modified with chitosan for target treatment of colorectal cancer.
Badran MM; Mady MM; Ghannam MM; Shakeel F
Int J Biol Macromol; 2017 Feb; 95():643-649. PubMed ID: 27908720
[TBL] [Abstract][Full Text] [Related]
26. Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.
Li Z; Huang H; Huang L; Du L; Sun Y; Duan Y
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28406431
[TBL] [Abstract][Full Text] [Related]
27. Surface-modified PLGA nanoparticles with chitosan for oral delivery of tolbutamide.
Shi Y; Xue J; Jia L; Du Q; Niu J; Zhang D
Colloids Surf B Biointerfaces; 2018 Jan; 161():67-72. PubMed ID: 29040836
[TBL] [Abstract][Full Text] [Related]
28. [Formulation and process optimization of doxorubicin-loaded PLGA nanoparticles and its in vitro release].
Li JL; Zheng CL; Liu JP; Zhu JB
Yao Xue Xue Bao; 2013 May; 48(5):759-66. PubMed ID: 23888702
[TBL] [Abstract][Full Text] [Related]
29. Preparation, characterization and uptake of PEG-coated, muco-inert nanoparticles in HGC-27 cells, a mucin-producing, gastric-cancer cell line.
Lin D; Li G; Qin L; Wen Z; Wang J; Sun X
J Biomed Nanotechnol; 2013 Dec; 9(12):2017-23. PubMed ID: 24266257
[TBL] [Abstract][Full Text] [Related]
30. Development of bicalutamide-loaded PLGA nanoparticles: preparation, characterization and in-vitro evaluation for the treatment of prostate cancer.
Ray S; Ghosh Ray S; Mandal S
Artif Cells Nanomed Biotechnol; 2017 Aug; 45(5):944-954. PubMed ID: 27327352
[TBL] [Abstract][Full Text] [Related]
31. Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles.
Lee C; Seo J; Hwang HS; Thao LQ; Lee S; Lee ES; Lee EH; Choi HG; Youn YS
Biomed Pharmacother; 2016 Mar; 78():226-233. PubMed ID: 26898446
[TBL] [Abstract][Full Text] [Related]
32. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.
Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S
Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558
[TBL] [Abstract][Full Text] [Related]
33. Controlled synthesis of in-situ gold nanoparticles onto chitosan functionalized PLGA nanoparticles for oral insulin delivery.
Asal HA; Shoueir KR; El-Hagrasy MA; Toson EA
Int J Biol Macromol; 2022 Jun; 209(Pt B):2188-2196. PubMed ID: 35504421
[TBL] [Abstract][Full Text] [Related]
34. Formulation and optimization of topotecan nanoparticles: In vitro characterization, cytotoxicity, cellular uptake and pharmacokinetic outcomes.
Padhi S; Kapoor R; Verma D; Panda AK; Iqbal Z
J Photochem Photobiol B; 2018 Jun; 183():222-232. PubMed ID: 29729631
[TBL] [Abstract][Full Text] [Related]
35. Cell Line and Augument Cellular Uptake Study of Statistically Optimized Sustained Release Capecitabine Loaded Eudragit S100/PLGA(poly(lacticco- glycolic acid)) Nanoparticles for Colon Targeting.
Pandey S; Vijayendra Swamy SM; Ubaid Ulla UM; Gupta A; Patel H; Yadav JS
Curr Drug Deliv; 2017 Sep; 14(6):887-899. PubMed ID: 27538461
[TBL] [Abstract][Full Text] [Related]
36. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes.
Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS
Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850
[TBL] [Abstract][Full Text] [Related]
37. N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption.
Sheng J; Han L; Qin J; Ru G; Li R; Wu L; Cui D; Yang P; He Y; Wang J
ACS Appl Mater Interfaces; 2015 Jul; 7(28):15430-41. PubMed ID: 26111015
[TBL] [Abstract][Full Text] [Related]
38. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-co-glycolide) copolymer nanospheres as DNA carriers.
Guan XP; Quan DP; Liao KR; Tao Wang ; Peng Xiang ; Mai KC
J Biomater Appl; 2008 Jan; 22(4):353-71. PubMed ID: 17494965
[TBL] [Abstract][Full Text] [Related]
39. Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles.
Chung TW; Wang SS; Tsai WJ
Biomaterials; 2008 Jan; 29(2):228-37. PubMed ID: 17953984
[TBL] [Abstract][Full Text] [Related]
40. PLGA Nanoparticle Platform for Trans-Ocular Barrier to Enhance Drug Delivery: A Comparative Study Based on the Application of Oligosaccharides in the Outer Membrane of Carriers.
Jiang G; Jia H; Qiu J; Mo Z; Wen Y; Zhang Y; Wen Y; Xie Q; Ban J; Lu Z; Chen Y; Wu H; Ni Q; Chen F; Lu J; Wang Z; Li H; Chen J
Int J Nanomedicine; 2020; 15():9373-9387. PubMed ID: 33262593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
